25 February 2025 in Neurology
Stacked proportional bar graphs (nicknamed "Grotta bars") are commonly used to visualize functional outcome scales in stroke research and are also used in other domains of neurology research. While lending themselves to a straightforward causal interpretation in ideal randomized controlled trials, in observational studies, Grotta bars cannot be generally interpreted causally if they show unadjusted, confounded comparisons. In a sample of recent observational neurology studies with confounding-adjusted effect estimates, we aimed to determine the frequency with which Grotta bars were used to visualize functional outcomes and how often unadjusted Grotta bars were presented without an accompanying adjusted version. We also assessed the methods used to generate adjusted Grotta bars. We identified the 15 top-ranked clinical neurology journals, according to journal impact factor, publishing full-length original research in English. Using PubMed, we retrieved all records published in these journals between 2020 and 2021 after applying a filter for observational studies. We included and systematically examined all observational studies aiming to identify a cause-and-effect relationship with an ordinal functional outcome and confounding-adjusted effect estimate. We determined whether at least 1 comparison using Grotta bars was present, whether the visualized comparisons were adjusted, and which adjustment strategies were applied to generate these graphs. A total of 250 studies met all inclusion criteria. Of these, 93 (37.2%) used Grotta bars to depict functional outcome scale distributions, with 76 (81.7%) presenting only Grotta bars without model-based adjustment. These bars were most commonly presented in studies with stroke patient populations; 87 of 192 studies (45.3%) presented Grotta bars. Among the 17 studies that presented Grotta bars adjusted using a model, the adjustment strategies included propensity score matching (n = 10; 58.8%), regression (n = 6; 35.3%), and inverse probability weighting (n = 1; 5.9%). Studies that presented adjusted associations for functional outcomes commonly showed only unadjusted Grotta bars, which alone have little value for causal questions. In observational research, Grotta bars are most informative if an adjusted version, aligning with adjusted effect estimates, is presented directly alongside the unadjusted version. Based on our findings, we offer recommendations to help authors generate more informative Grotta bars and to facilitate correct interpretation for readers.
11 December 2025 in International Journal of Gynecological Cancer
Paclitaxel is a standard therapy in platinum-resistant ovarian cancer, but nab-paclitaxel, a solvent-free formulation with a favorable toxicity profile approved in other tumors, has not been evaluated against solvent-based paclitaxel (sb-paclitaxel) in this setting. This study compares efficacy and safety of nab-paclitaxel to sb-paclitaxel monotherapy in platinum-resistant ovarian cancer to inform clinical decision-making and guidelines. A mixed-methods approach combined a systematic literature review with expert discussions. Study selection followed 2 sample frames: (1) randomized controlled trials for sb-paclitaxel monotherapy published after the Cochrane review (2022), and (2) randomized and observational studies for nab-paclitaxel monotherapy, identified through searches of major databases through October 2024. Findings were discussed in 2 inter disciplinary, patient-centered workshops. These workshops integrated trial data with real-world experience and expert judgment to evaluate treatment outcomes, safety, and research gaps. The review identified no randomized head-to-head trials comparing nab-paclitaxel and sb-paclitaxel in platinum-resistant ovarian cancer. No new randomized trials of sb-paclitaxel were published since the Cochrane review. However, a related trial was identified comparing weekly with 3-weekly sb-paclitaxel. It reported improved survival and reduced hematologic toxicity with weekly dosing, although quality-of-life data were limited. Existing studies on nab-paclitaxel are limited to single-arm and combination trials with heterogeneous populations and treatment regimens. The experts agree that indirect evidence from other tumors (breast/gastric cancer), demonstrates comparable efficacy between the 2 formulations, with nab-paclitaxel showing a favorable safety profile by avoiding Cremophor® EL-related toxicities. The consensus was that nab-paclitaxel's tolerability allows higher dosing and may enhance quality of life. Regulatory and reimbursement challenges persist without approval for nab-paclitaxel monotherapy in platinum-resistant ovarian cancer. Despite the absence of direct trials, experts considered evidence sufficient to support nab-paclitaxel as a viable alternative to sb-paclitaxel in platinum-resistant ovarian cancer with comparable efficacy, safety, and fewer hypersensitivity reactions. Additional randomized trials were not deemed necessary.